Giampaolo Merlini focuses on Amyloidosis, Internal medicine, AL amyloidosis, Amyloid and Pathology. Giampaolo Merlini combines subjects such as Brain natriuretic peptide, Endocrinology, Transthyretin, Cardiomyopathy and Immunology with his study of Amyloidosis. His Internal medicine research incorporates elements of Gastroenterology, Surgery and Oncology.
His work carried out in the field of AL amyloidosis brings together such families of science as Immunofixation, Survival analysis, Chemotherapy and Hematologic Response. His biological study deals with issues like Fibril, which deal with fields such as Protein folding. The study incorporates disciplines such as Cryoglobulinemia and Monoclonal in addition to Pathology.
His primary areas of study are Internal medicine, Amyloidosis, AL amyloidosis, Pathology and Amyloid. His studies deal with areas such as Gastroenterology, Surgery and Oncology as well as Internal medicine. The concepts of his Amyloidosis study are interwoven with issues in Immunoglobulin light chain, Transthyretin, Immunology and Monoclonal.
His Transthyretin research incorporates themes from Polyneuropathy, Cardiomyopathy and Tafamidis. His AL amyloidosis study incorporates themes from Hematologic Response, Chemotherapy, Melphalan and Dexamethasone. Giampaolo Merlini has researched Amyloid in several fields, including Fibril and Biochemistry.
Giampaolo Merlini mostly deals with Amyloidosis, Internal medicine, AL amyloidosis, Immunoglobulin light chain and Pathology. His Amyloidosis research integrates issues from Polyneuropathy, Bioinformatics, Transthyretin and Disease, Amyloid. The Internal medicine study combines topics in areas such as Gastroenterology and Oncology.
His research in AL amyloidosis intersects with topics in Monoclonal, Cyclophosphamide, Hematologic Response and Daratumumab. His work deals with themes such as Molecular biology, Biophysics, Biochemistry and Plasma cell, which intersect with Immunoglobulin light chain. The various areas that Giampaolo Merlini examines in his Bortezomib study include Melphalan, Autologous stem-cell transplantation, Surgery and Transplantation.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International uniform response criteria for multiple myeloma
B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade.
Leukemia (2006)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)
Molecular mechanisms of amyloidosis.
Giampaolo Merlini;Vittorio Bellotti.
The New England Journal of Medicine (2003)
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
Morie A. Gertz;Ray Comenzo;Rodney H. Falk;Jean Paul Fermand.
American Journal of Hematology (2005)
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
A. Dispenzieri;R. Kyle;G. Merlini;J. S. Miguel.
Leukemia (2009)
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.
Julian D. Gillmore;Mathew S. Maurer;Rodney H. Falk;Giampaolo Merlini.
Circulation (2016)
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Mathew S. Maurer;Jeffrey H. Schwartz;Balarama Gundapaneni;Perry M. Elliott.
The New England Journal of Medicine (2018)
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
R A Kyle;B G M Durie;S V Rajkumar;O Landgren.
Leukemia (2010)
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
Giovanni Palladini;Angela Dispenzieri;Morie A. Gertz;Shaji Kumar.
Journal of Clinical Oncology (2012)
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Merrill D. Benson;Márcia Waddington-Cruz;John L. Berk;Michael Polydefkis.
The New England Journal of Medicine (2018)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Mayo Clinic
Mayo Clinic
National and Kapodistrian University of Athens
University College London
University College London
Indiana University
University of Ferrara
Mayo Clinic
Columbia University
University of Pavia
TU Dresden
Tohoku University
Centre national de la recherche scientifique, CNRS
University of Florence
Kyushu University
University of Melbourne
Leipzig University
University of Kent
University of Ferrara
University of Adelaide
Arizona State University
Georgetown University
Radboud University Nijmegen
Chinese University of Hong Kong
Lamar University
University of Michigan–Ann Arbor